Health Canada issues NOC to J&J's CARVYKTI for multiple myeloma [Yahoo! Finance]
340B Legal Challenges Highlight The Appetite For Innovation That Supports The Program's Goals [Forbes]
Antihistamine Drugs Industry Report 2025-2030: A $381 Million Opportunity - Johnson & Johnson, Sanofi, Pfizer, and Bayer Experiencing Notable Growth Driven by Substantial R&D Investments [Yahoo! Finance]
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor [Yahoo! Finance]
Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor